Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

Microbiome: Gut microbiota sways response to cancer immunotherapy

(2018) Ashley York   NATURE REVIEWS MICROBIOLOGY

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways

(2017) Kai Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

(2017) Jianjun Gao et al.   NATURE MEDICINE

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

(2017) Leore T. Geller et al.   SCIENCE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk

(2017) Derek V. Seidel et al.   SEMINARS IN CANCER BIOLOGY

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells

(2017) Haifa Shen et al.   SEMINARS IN IMMUNOLOGY

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation

(2017) Josefa A. Rodríguez   Oncology Letters

Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy

(2017) Matthias Van Woensel et al.   Scientific Reports

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

(2016) Colin W. Steele et al.   CANCER CELL

Current Challenges in Cancer Treatment

(2016) Jon Zugazagoitia et al.   CLINICAL THERAPEUTICS

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia

(2016) C. Mu et al.   MOLECULAR CANCER THERAPEUTICS

An injectable nanoparticle generator enhances delivery of cancer therapeutics

(2016) Rong Xu et al.   NATURE BIOTECHNOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

(2016) Yuta Kondo et al.   ORAL ONCOLOGY

Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors

(2016) Joanna Kopecka et al.   Oncotarget

PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

(2016) Zhenhua Li et al.   Journal of Cancer

Immunotherapy Approaches in Cancer Treatment

(2015) Pavel Klener et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Stromal biology and therapy in pancreatic cancer: a changing paradigm

(2015) Albrecht Neesse et al.   GUT

CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy

(2015) Shaohua Yao et al.   HUMAN GENE THERAPY

A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System

(2015) Maurizio Chiriva-Internati et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Cancer and the Immune System: Basic Concepts and Targets for Intervention

(2015) Drew Pardoll   SEMINARS IN ONCOLOGY

New approaches for cancer immunotherapy

(2015) Ayfer Karlitepe et al.   TUMOR BIOLOGY

Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique

(2014) Chiara Schiraldi et al.   CANCER BIOLOGY & THERAPY

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

Prebiotics: A Potential Treatment Strategy for the Chemotherapy-damaged Gut?

(2014) Hanru Wang et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Bone marrow endothelium-targeted therapeutics for metastatic breast cancer

(2014) Junhua Mai et al.   JOURNAL OF CONTROLLED RELEASE

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

(2014) Luca Gianni et al.   LANCET ONCOLOGY

Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling

(2014) B. Dave et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Impact of Diet and Lifestyle on Gut Microbiota and Human Health

(2014) Michael Conlon et al.   Nutrients

Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

(2013) B. Kwong et al.   CANCER RESEARCH

Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery

(2013) H. Shen et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapies, their safety and toxicity

(2013) Gheath Alatrash et al.   Expert Opinion On Drug Safety

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

(2013) Aman U Buzdar et al.   LANCET ONCOLOGY

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer

(2012) Annemarie Boleij et al.   BIOLOGICAL REVIEWS

Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains

(2012) J. J. Trowbridge et al.   GENES & DEVELOPMENT

Prebiotics and the Health Benefits of Fiber: Current Regulatory Status, Future Research, and Goals

(2012) Amy M. Brownawell et al.   JOURNAL OF NUTRITION

New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study

(2011) Monica Marra et al.   BIOTECHNOLOGY ADVANCES

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

(2011) Monica Marra et al.   Nanomedicine-Nanotechnology Biology and Medicine

Self-assembly nanoparticles for the delivery of bisphosphonates into tumors

(2010) G. Salzano et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Zoledronic acid: an unending tale for an antiresorptive agent

(2009) Michele Caraglia et al.   EXPERT OPINION ON PHARMACOTHERAPY